Aiden Reiter, a partner in the Unhedged Newsletter, and Oliver Barnes, the Pharmaceuticals correspondent for the Financial Times, dive into the soaring stock prices of Eli Lilly and Novo Nordisk, with increases of 750% and 360%, respectively. They discuss the booming market for GLP-1 weight loss drugs, their societal impacts, and the competitive landscape between these pharmaceutical giants. The conversation also touches on the economic implications of these medications, from high costs to insurance challenges, and the future of diabetes treatment.

Oliver Barnes, a seasoned US pharmaceutical correspondent for the Financial Times, teams up with Maria Heeter, a deals expert, to dissect a tumultuous activist investment campaign against Pfizer. They delve into the unexpected blunders, like a mysterious email that turned the tide. The duo discusses Pfizer's post-pandemic struggles, challenges in corporate governance, and how missteps can derail activist strategies in the pharma sector. Tune in for a gripping look at the high-stakes world where boardroom loyalty meets investor ambition!